Browsing: and the medical director of the Adult Sickle Cell Program at Smilow Cancer Hospital at the Yale New Haven Health System in Connecticut.

      The Food and Drug Administration on Friday approved a new gene-editing therapy to treat Sickle Cell Disease, a debilitating blood disorder that affects at least 100,000 Americans, most of whom are Black. The treatment, called Casgevy, is the first approved medicine in the U.S. to use the groundbreaking gene-editing tool CRISPR to alter DNA.